Skip to main content

Table 3 Best overall response (safety analysis set)

From: Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer

Parameter Patients with response, n (%)
[95% confidence interval]
Stratum 1
(n = 16)
Stratum 2
(n = 8)
Stratum 3
(n = 2)
Overall
(n = 26)
Response (CR + PR) rate 1 (6.3)
[0.2–30.2]
0
[0.0–36.9]
0
[0.0–84.2]
1 (3.8)
[0.1–19.6]
Best overall response
 CR 0
[0.0–20.6]
0
[0.0–36.9]
0
[0.0–84.2]
0
[0.0–13.2]
 PR 1 (6.3)
[0.2–30.2]
0
[0.0–36.9]
0
[0.0–84.2]
1 (3.8)
[0.1–19.6]
 SD 8 (50.0)
[24.7–75.3]
3 (37.5)
[8.5–75.5]
1 (50.0)
[1.3–98.7]
12 (46.2)
[26.6–66.6]
 PD 7 (43.8)
[19.8–70.1]
4 (50.0)
[15.7–84.3]
1 (50.0)
[1.3–98.7]
12 (46.2)
[26.6–66.6]
 NE 0
[0.0–20.6]
1 (12.5)
[0.3–52.7]
0
[0.0–84.2]
1 (3.8)
[0.1–19.6]
  1. Confirmed response according to Response Evaluation Criteria for Solid Tumors (RECIST) version 1.1
  2. Abbreviations: CR complete response, NE not evaluable, PD progressive disease, PR partial response, SD stable disease